Table 3 BC patients stratified by osteoporotic fracture occurrence
Variable | Osteoporotic fracture (n=62) | No osteoporotic fracture (n=596) | P value |
|---|---|---|---|
a: Baseline characteristics (n=658) | |||
Age at BC diagnosis (mean±s.d.) | 62.6±9.3 | 60.0±11.1 | 0.082a |
BMI (mean±s.d.) | 29.3±4.8 | 29.9±5.8 | 0.343a |
BMI, N (%) | |||
⩽30 | 39 (62.9) | 337 (56.5) | 0.442b |
30.1–35 | 15 (24.2) | 147 (24.7) | |
35.1–40 | 7 (11.3) | 73 (12.2) | |
⩾40.1 | 1 (1.6) | 39 (6.5) | |
HRT treatment, N (%) (n=296) per history | 6 (25.0) (n=24) | 71 (26.1) (n=272) | 0.906b |
HRT (during 2 years before BMD) according to drug purchase, N (%) | 13 (21.0) | 127 (21.3) | 0.950b |
Past/current oral contraceptives use, N (%) (n=125) | 3 (25.0) (n=12) | 26 (23.0) (n=113) | 0.877b |
b: BC grade, stage, and treatment | |||
T stage, N (%) (n=638) | |||
T in situ | 7 (11.9) | 48 (8.3) | 0.394b |
T0 | 0 (0) | 7 (1.2) | |
T1 | 39 (66.1) | 331 (57.2) | |
T2 | 12 (20.3) | 160 (27.6) | |
T3 | 0 (0) | 21 (3.6) | |
T4 | 0 (0) | 6 (1.0) | |
Tx | 1 (1.7) | 6 (1.0) | |
Stage, N (%) (n=636) | |||
0/I | 37 (63.8) | 302 (52.2) | 0.038b |
II | 21 (36.2) | 225 (38.9) | |
III/IV | 0 (0) | 51 (8.8) | |
Histology, N (%) (n=639) | |||
DCIS (only) | 7 (11.9) | 48 (8.3) | 0.467b |
Invasive duct carcinoma | 47 (79.7) | 468 (80.7) | |
Invasive lobular carci | 2 (3.4) | 41 (7.1) | |
Other | 3 (5.1) | 24 (4.2) | |
Histological grade, N (%) (n=429) | |||
Low | 6 (14.0) | 106 (27.5) | 0.048b |
Intermediate | 25 (58.1) | 154 (39.9) | |
High | 12 (27.9) | 126 (32.6) | |
Immunohistochemistry, N (%) | |||
ER positive (n=562) | 46 (86.8) | 426 (83.7) | 0.558b |
PR positive (n=552) | 42 (80.8) | 352 (70.4) | 0.115b |
Her-2 (n=436) | |||
0/+1 | 30 (76.9) | 313 (78.8) | 0.192b |
+2 and CISH negative | 0 (0) | 12 (3.0) | |
+2 and CISH unknown | 6 (15.4) | 28 (7.1) | |
+3/CISH positive | 3 (7.7) | 44 (11.1) | |
Triple negative (n=526) | 1 (2.0) | 28 (5.9) | 0.253b |
Chemotherapy (neo or adjuvant) N (%)(n=636) | 15 (25.0) | 260 (45.1) | 0.003b |
Hormonal therapy (neo or adjuvant) (n=636) N (%) | |||
Tamoxifen alone | 31 (51.7) | 198 (34.4) | 0.007b |
Aromatase inhibitors alone | 1 (1.7) | 46 (8.0) | |
Tamoxifen+aromatase inhibitors | 20 (33.3) | 206 (35.8) | |
Other | 1 (1.7) | 1 (0.2) | |
Any tamoxifen treatment, N (%) | 51 (85.0) | 404 (70.1) | 0.015b |
Any aromatase inhibitors treatment, N (%) | 21 (35.0) | 252 (43.8) | 0.193b |
Radiotherapy (neo or adjuvant), N (%) (n=636) | 42 (70.0) | 440 (76.4) | 0.272b |
Trastuzumab (neo or adjuvant), N (%) (n=635) | 0 (0) | 16 (2.8) | 0.195b |
c: BMD | |||
BMD, g/cm2 (mean±s.d.) | |||
Femoral neck | 0.77±0.11 | 0.83±0.12 | <0.001a |
Total hip | 0.84±0.13 | 0.91±0.14 | <0.001a |
Spine | 0.96±0.15 | 1.03±0.17 | 0.002a |
BMD T-score (mean±s.d.) | |||
Femoral neck | −1.72±0.94 | −1.22±1.04 | <0.001a |
Total hip | −1.32±1.12 | −0.79±1.13 | <0.001a |
Spine | −1.80±1.23 | −1.23±1.42 | 0.002a |
BMD Z-score (mean±s.d.) | |||
Femoral neck | −0.37±0.84 | −0.05±0.93 | 0.010a |
Total hip | −0.16±1.03 | 0.18±1.02 | 0.013a |
Spine | −0.29±1.34 | 0.13±1.49 | 0.035a |
